My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Emergent BioSolutions Inc. Common Stock (NY:EBS)

9.600 +0.510 (+5.61%)
Official Closing Price Updated: 7:00 PM EDT, Oct 15, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 739,142
Open 9.260
Bid (Size) 9.450 (7)
Ask (Size) 9.830 (1)
Prev. Close 9.090
Today's Range 9.240 - 9.690
52wk Range 4.020 - 12.73
Shares Outstanding 53,700,000
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Emergent BioSolutions to Report Third Quarter 2025 Financial Results on October 29, 2025
From Emergent BioSolutions
Via GlobeNewswire
12 Health Care Stocks Moving In Thursday's After-Market Session
 
Via Benzinga

Performance

YTD
-6.5%
-6.5%
1 Month
+20.0%
+20.0%
3 Month
+37.3%
+37.3%
6 Month
+107.8%
+107.8%
1 Year
+4.5%
+4.5%

More News

Read More
Emergent BioSolutions Recognizes Several Important Observances to Help Save Lives from Opioid Poisoning and Encourages Preparedness with Life-Saving Naloxone
From Emergent BioSolutions
Via GlobeNewswire
Earnings Scheduled For August 6, 2025
Via Benzinga
A Preview Of Emergent BioSolutions's Earnings
Via Benzinga
3 Small-Cap Stocks to Watch After the Fed’s Rate Cuts
Via MarketBeat
Topics Economy
Emergent BioSolutions Stock Rises After Receiving Fresh International Purchase Orders: Retail Says Stock Is ‘Significantly Undervalued’
Via Stocktwits
Emergent BioSolutions Secures $29 Million in MCM Product Orders from International Government Partner
From Emergent BioSolutions
Via GlobeNewswire
Emergent BioSolutions Secures $17 Million Contract Modification for Oral Suspension TEMBEXA® (brincidofovir), a Smallpox Antiviral, and Strengthens Overall U.S. Supply Chain
From Emergent BioSolutions
Via GlobeNewswire
Emergent BioSolutions Receives New Contract Modification for ACAM2000®, (Smallpox and Mpox (Vaccinia) Vaccine, Live) from the U.S. Government, Further Demonstrating Importance of Public Health Preparedness
From Emergent BioSolutions
Via GlobeNewswire
Emergent BioSolutions Awarded $30 Million Contract Modification for CYFENDUS® (Anthrax Vaccine Adsorbed, Adjuvanted), a Two-Dose Anthrax Vaccine for Post-Exposure Prophylaxis Use
From Emergent BioSolutions
Via GlobeNewswire
Emergent BioSolutions Underscores Continued Support of Increasing Naloxone Awareness Through Public Education Campaign on International Overdose Awareness Day
From Emergent BioSolutions
Via GlobeNewswire
Emergent BioSolutions to Participate in Upcoming Investor Conferences
From Emergent BioSolutions
Via GlobeNewswire
Emergent BioSolutions Supports Voices for Awareness and Facing Fentanyl Now on August 21, 2025 for National Fentanyl Prevention and Awareness Day™
From Emergent BioSolutions
Via GlobeNewswire
Big Rallies Brewing? 3 Analyst Favorites to Watch Closely
Via MarketBeat
Thursday's session: top gainers and losers
Via Chartmill
12 Health Care Stocks Moving In Thursday's Intraday Session
Via Benzinga
Traders are paying attention to the gapping stocks in Thursday's session.
Via Chartmill
12 Health Care Stocks Moving In Wednesday's After-Market Session
Via Benzinga
Emergent BioSolutions Reports Second Quarter 2025 Financial Results
From Emergent BioSolutions
Via GlobeNewswire
New Publication in Expert Review of Anti-infective Therapy Evaluates Brincidofovir as Potential Antiviral Treatment for Mpox
From Emergent BioSolutions
Via GlobeNewswire
Emergent Applauds Availability of Over-the-Counter Naloxone in U.S. House of Representatives
From Emergent BioSolutions
Via GlobeNewswire
Emergent BioSolutions to Report Second Quarter 2025 Financial Results on August 6, 2025
From Emergent BioSolutions
Via GlobeNewswire
Emergent BioSolutions Stock Rises After New US Order For Smallpox Complication Therapy
Via Stocktwits
Emergent BioSolutions Secures $51.9 Million Contract Modification Award for CNJ-016® [Vaccinia Immune Globulin Intravenous (Human)] (VIGIV) as part of U.S. Biodefense Preparedness Efforts
From Emergent BioSolutions
Via GlobeNewswire

Frequently Asked Questions

Is Emergent BioSolutions Inc. Common Stock publicly traded?
Yes, Emergent BioSolutions Inc. Common Stock is publicly traded.
What exchange does Emergent BioSolutions Inc. Common Stock trade on?
Emergent BioSolutions Inc. Common Stock trades on the New York Stock Exchange
What is the ticker symbol for Emergent BioSolutions Inc. Common Stock?
The ticker symbol for Emergent BioSolutions Inc. Common Stock is EBS on the New York Stock Exchange
What is the current price of Emergent BioSolutions Inc. Common Stock?
The current price of Emergent BioSolutions Inc. Common Stock is 9.600
When was Emergent BioSolutions Inc. Common Stock last traded?
The last trade of Emergent BioSolutions Inc. Common Stock was at 10/15/25 07:00 PM ET
What is the market capitalization of Emergent BioSolutions Inc. Common Stock?
The market capitalization of Emergent BioSolutions Inc. Common Stock is 515.52M
How many shares of Emergent BioSolutions Inc. Common Stock are outstanding?
Emergent BioSolutions Inc. Common Stock has 516M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.